









Markets
/
Stocks
/
nasdaq-chrs
/

Coherus BioSciences Inc

CHRS

2.140USD

+0.050+2.39%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

248.75MMarket Cap

1.61P/E TTM



Coherus BioSciences Inc

2.140

+0.050+2.39%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Coherus BioSciences Inc

Currency: USD Updated: 2026-02-06

Key Insights

Coherus BioSciences Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 93 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 5.67.In the medium term, the stock price is expected to trend up.Despite strong stock market performance and technicals over the past month, the fundamentals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Coherus BioSciences Inc's Score

Industry at a Glance

Industry Ranking

93 / 159

Overall Ranking

251 / 4521

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Coherus BioSciences Inc Highlights

StrengthsRisks

Coherus Oncology, Inc., formerly Coherus BioSciences, Inc., is a fully integrated commercial-stage oncology company with an approved PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. LOQTORZI (toripalimab-tpzi) is its immuno-oncology franchise. LOQTORZI is the FDA-approved treatment indicated in combination with chemotherapy for recurrent or metastatic nasopharyngeal carcinoma (NPC) and is also in development for the treatment of additional tumor types. Its CHS-114 pipeline is a highly selective cytolytic CCR8 antibody that specifically binds and preferentially depletes CCR8+ tumor regulatory T cells (Tregs) with no off-target binding. Its Casdozokitug pipeline is a first-in-class, clinical-stage IL-27 antagonist, with demonstrated monotherapy activity in treatment-refractory NSCLC and clear cell renal cell carcinoma (ccRCC) and combination activity in hepatocellular carcinoma (HCC).

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 26.50% year-on-year.

Turnaround to Profit

The company's performance has turned profitable, with the latest annual net income of USD .

Overvalued

The company’s latest PE is 1.61, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 54.05M shares, increasing 0.16% quarter-over-quarter.

Held by PRFDX

Star Investor PRFDX holds 10.32K shares of this stock.

Analyst Rating

Based on 6 analysts

Buy

Current Rating

5.667

Target Price

+155.26%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Coherus BioSciences Inc is 5.59, ranking 155 out of 159 in the Pharmaceuticals industry. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 11.57M, representing a year-over-year decrease of 83.65%, while its net profit experienced a year-over-year decrease of 230.49%.

Score

Industry at a Glance

Previous score

5.59

Change



Financials

4.92

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.70

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.83

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

5.40

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.07

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Coherus BioSciences Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Coherus BioSciences Inc is 7.59, ranking 60 out of 159 in the Pharmaceuticals industry. Its current P/E ratio is 1.61, which is 313.89% below the recent high of 6.67 and 2705.58% above the recent low of -41.99.

Score

Industry at a Glance

Previous score

7.59

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 93/159

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Coherus BioSciences Inc is 8.33, ranking 43 out of 159 in the Pharmaceuticals industry. The average price target is 5.00, with a high of 6.00 and a low of 4.00.

Score

Industry at a Glance

Previous score

8.33

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 6 analysts

Buy

Current Rating

5.667

Target Price

+155.26%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

173

Total

Median

Average

Company name

Ratings

Analysts

Coherus BioSciences Inc

CHRS

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Eli Lilly and Co

LLY

Gilead Sciences Inc

GILD

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Coherus BioSciences Inc is 7.21, ranking 74 out of 159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 2.67 and the support level at 1.56, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.29

Change

-0.08

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(3)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

-0.004

Neutral

RSI(14)

59.306

Neutral

STOCH(KDJ)(9,3,3)

27.712

Sell

ATR(14)

0.247

High Vlolatility

CCI(14)

10.999

Neutral

Williams %R

43.039

Buy

TRIX(12,20)

1.993

Buy

StochRSI(14)

26.593

Buy

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

2.168

Sell

MA10

2.233

Sell

MA20

1.954

Buy

MA50

1.587

Buy

MA100

1.563

Buy

MA200

1.253

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Coherus BioSciences Inc is 5.00, ranking 73 out of 159 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 69.95%, representing a quarter-over-quarter decrease of 11.71%. The largest institutional shareholder is The Vanguard, holding a total of 10.03M shares, representing 8.30% of shares outstanding, with 13.74% decrease in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

10.32M

-2.36%

BlackRock Institutional Trust Company, N.A.

8.06M

-2.19%

Bering Capital LLC

7.59M

Satterfield (Thomas A Jr)

6.01M

Tang Capital Management, LLC

5.10M

Kohlberg Kravis Roberts & Co. L.P.

3.04M

Geode Capital Management, L.L.C.

2.74M

+2.42%

State Street Investment Management (US)

2.22M

+0.22%

CM Management, LLC

2.10M

-6.67%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Coherus BioSciences Inc is 2.69, ranking 122 out of 159 in the Pharmaceuticals industry. The company's beta value is 1.02. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.